Southwestern Internal Medicine Conference: bone disease in kidney failure: diagnosis and management.
Recent technologic and therapeutic advances have improved the life of the patient with end-stage renal disease. High efficiency and high-flux hemodialyzer membranes have shortened the time required to dialyze, and recombinant erythropoietin has all but eliminated anemia as a major cause of morbidity, but the problem of renal osteodystrophy remains. The following discussion examines the spectrum of bone and joint disease in the patient with end-stage renal disease. The diagnostic and therapeutic strategies currently being tried in the management of these disorders are discussed.
Cronin
R E
RE
Veterans Affairs Medical Center, Dallas, TX 75216.
D000368:Aged; D001706:Biopsy; D001847:Bone Diseases / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D001842:Bone and Bones / Q000473:pathology; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000097:blood; D002614:Chelating Agents / Q000627:therapeutic use; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications / Q000503:physiopathology; D000075202:Contraindications; D003676:Deferoxamine / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016105:Parathyroidectomy; D010710:Phosphates / Q000097:blood; D006435:Renal Dialysis
D002614:Chelating Agents; D010710:Phosphates; D002117:Calcitriol; D003676:Deferoxamine; D002118:Calcium